Interleukin Genetics' PST genetic test approved for marketing in New York

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it has received approval by the State of New York's Department of Health for the Company to sell in New York its PST Genetic Test that determines predisposition to severe periodontal disease in individuals. The test has been available in all other States in the U.S. However, through its Clinical Laboratory Evaluation Program (CLEP), New York monitors the accuracy and reliability of results of laboratory tests, including genetic tests, on specimens obtained within the state, setting one of the highest accreditation standards in the country for genetic testing companies.

Interleukin Genetics currently distributes its PST genetic test to dentists through a licensing agreement with OralDNA Labs, a subsidiary of Quest Diagnostics, Inc. This approval will further expand OralDNA Labs' reach to the dentist community with the PST test.

"We are pleased to have met New York's standard for both our laboratory practices and our PST test. This approval by New York further supports our commitment to provide genetic tests that offer strong clinical value," said Lewis H. Bender, CEO, Interleukin Genetics. "PST along with our Heart Health now both meet New York State's unique criteria."

The PST Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST is the only genetic test available that is capable of identifying which patients are at increased risk for developing severe periodontal disease and can provide dentists and hygienists with important clinical information about their patients. The test is especially useful in patients with early signs of periodontal disease, including recurrent gingivitis and early-to-moderate periodontitis to identify patients more likely to develop severe periodontitis and associated complications.